4
Management
General Recommendations
➤ In patients with active infection, CAR T-cell infusion should be
delayed until the infection has been successfully treated or
controlled.
➤ Inactivated influenza and COVID-19 vaccination of patients and
family members is recommended, as per local guidelines and ASCO
guidance*. Although the immunogenicity and efficacy of COVID-19
vaccines are uncertain in patients receiving immunomodulatory
agents, the potential for benefit from vaccination likely outweighs
these uncertainties for most patients.
➤ Strongly consider evaluation and/or transfer to a specialty center
that has experience with CAR T toxicity management. If treated in an
outpatient setting, it is advisable that patients remain within 2 hours
of the treating center for 4–8 weeks post-therapy and should return to
their treating center upon experiencing any toxicities.
* https://www.asco.org/sites/new-www.asco.org/files/content-files/covid-19/2021-MSK-COVID19-
VACCINE-GUIDELINES.pdf
